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Abstract 
Aim: To evaluate whether berberine hydrochloride (BBR) could modify the phar‑
macokinetic profiles of midazolam (MDZ), a substrate of CYP3A, and rhodamine 123 
(Rh123), a substrate of P‑glycolprotein (P‑gp), in male rats.
Methods: The rats were given with varied does of BBR or 75 mg/kg ketoconazole as 
a positive control for 10 days by intragastric administration. Single‑pass duodenum 
perfusion of 20 mg/kg MDZ and inguinal artery canulated rats were used in the study. 
Plasma concentrations of MDZ and 1′‑hydroxymidazolam (1′‑OH‑MDZ) were ana‑
lyzed by high performance liquid chromatography (HPLC). The rats were given with 
varied does of BBR or 4 mg/kg verapamil as a positive control for 10 days by intragas‑
tric administration. Blood was obtained from the caudal vein of rats after single‑pass 
intragastric administration of 5 mg/kg Rh123. HPLC was used to analyze the plasma 
concentrations of Rh123.
Results: BBR produced similar results as the ketoconazole (positive control group) 
with a dose‑dependent increase in the AUC(0−t) and AUMC (0−t) of midazolam except at 
the dose of 50 mg/kg (p < 0.01). And BBR could significantly increase the peak plasma 
concentrations (Cmax) of MDZ (p < 0.01), but reduce the clearance rate (CLz) and the 
apparent volume of the distribution (Vz) of MDZ (p < 0.05). The results also indicated 
that BBR had no significant impact on the half‑life period (t1/2) and the time to reach 
peak concentration (tmax). Meanwhile, BBR could dose‑dependently decrease AUC(0−t) 
and AUMC(0−t) of 1′‑OH‑MDZ significantly (p < 0.05), and expedite the clearance rate 
of 1′‑OH‑MDZ while gaining its apparent volume of distribution (p < 0.05), but had no 
significant impact on t1/2 and Tmax. The result also showed that BBR, except at the dose 
of 50 mg/kg, and the positive verapamil group could significantly increase the AUC(0−t) 
and AUC(0−∞) of Rh123 (p < 0.001), meanwhile raise Cmax of Rh123 and shorten its 
Vz inversely (p < 0.05). Additionally, pre‑treatment with BBR had no significant influ‑
ence with the half‑life period of Rh123, while significantly reduced its clearance rate 
(p < 0.05).
Conclusion: The metabolism of MDZ and Rh123 was controlled by BBR. The results 
were most likely due to the inhibition by BBR on CYP3A enzymes and P‑gp transporter.
Keywords: Berberine hydrochloride, CYP3A, P‑glycolprotein, Midazolam, Rhodamine 
123, Pharmacokinetics
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Background
Cytochrome P450 are important drug metabolism enzymes in  vivo, involved in the 
metabolism of some important endogenous substances and more than 50  % of the 
clinical medicine. P-glycoprotein (P-gp)-mediated drug efflux and cytochrome p450 
3A (CYP3A) metabolism within the P-glycoprotein (P-gp) mediats drug efflux and 
cytochrome P4503A (CYP3A) metabolism within the intestines creates a barrier that 
affects the absorption of many oral drugs (Benet et al. 1999; Zhou 2008). A number of 
studies have found that the change of the activity of P-gp will also cause the absorption 
and metabolism of P-gp substrates (Malati et al. 2012; Zhang et al. 2007). Therefore, a 
more in-depth understanding of the effects of drugs on the activity of CYP3A enzyme 
and P-gp will have an important significance on the evaluation of drug interaction.
In years of clinical practice, we had found that berberine hydrochloride (BBR) could 
significantly increase plasma concentration of cyclosporineA (CsA) in transplant recipi-
ents (Wu et  al. 2005; Xin et  al. 2006). Our studies showed that BBR could inhibit the 
CYP3A activity in vivo on rat and mouse liver, small intestine (Xin et al. 2004, 2005). We 
also confirmed that the pre-treated BBR combined with CsA or high doses of BBR alone 
could significantly alter mdr1a and mdr1b gene expression (Xin et al. 2002).
Based on the previous conclusion, the purpose of this experiment is to study the 
effects of BBR on CYP3A and P-gp in rats. Midazolam (MDZ), as an ideal CYP3A probe, 
has been widely used to evaluate the effects of drugs on CYP3A enzyme (Kim et al. 2002; 
Rogers et al. 2003; Xin et al. 2012). Rhodamine 123(Rh123) is the classic P-gp active sub-
strate, and its elimination in vivo was only related with the activity of P-gp (Bao et al. 
2012). Our laboratory had established detection methods for rat plasma midazolam, 
1′-hydroxymidazolam (1′-OH-MDZ), and the blood serum concentration of Rh123 (Li 
et al. 2012). We studied the effects of BBR on MDZ and Rh123 metabolism in rats to 
evaluate the effects of BBR on CYP3A activity and P-gp transporter.
Results and discussion
Effect of berberine on midazolam and its metabolite pharmacokinetic experiments in rat
Figure 1 below presented the time-plasma concentration variation trend of MDZ after 
pre-treated with other drugs. As Fig. 1 showed, rat plasma concentrations of MDZ in 
Fig. 1 The effect of multi‑dose of berberine or ketoconazole on the pharmacokinetics of midazolam in rats. 
Data present mean concentrations ± SD, n = 8
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oral BBR group and the positive ketoconazole group were higher than that in the neg-
ative group. Rat plasma concentrations of MDZ in the positive group (p  <  0.05) were 
significantly higher than that in the negative group except at the point of 2 min. In addi-
tion, the rat plasma concentrations of MDZ were higher than that in the negative group. 
Therefore, BBR could dose-dependently increase the plasma concentration of MDZ.
Figure 2 showed the time-plasma concentration variation trend of 1′-OH-MDZ after 
pre-treating with BBR or ketoconazole. As Fig. 2 showed, BBR and ketoconazole could 
decrease rat plasma concentrations of 1′-OH-MDZ. It has been shown that ketocona-
zole and BBR (100 and 200 mg/kg) could significantly decrease rat plasma concentration 
of 1′-OH-MDZ except at the points of 2 and 10 min (p < 0.05). Moreover, data showed a 
significant reduction of rat plasma concentration of 1′-OH-MDZ after giving 50 mg/kg 
BBR between the point 20 to 90 min (p < 0.05).
Pre-treated with BBR or ketoconazole could alter some pharmacokinetic parame-
ters of MDZ and 1′-OH-MDZ (Tables 1, 2). BBR at 200 and 100 mg/kg could decrease 
AUC(0−t) and AUMC(0−t)of MDZ significantly (p < 0.01) in a dose-dependent way, while 
BBR of three dose groups could significantly increase the peak plasma concentrations 
(Cmax) of MDZ (p  <  0.01). And all BBR groups could reduce the clearance rate (CLz) 
and apparent volume of distribution (Vz) of MDZ (p < 0.05), while it had no significant 
Fig. 2 The effect of multi‑dose of berberine or ketoconazole on the pharmacokinetics of 1′‑hydroxymida‑
zolam in rats. Data present mean concentrations ± SD, n = 8
Table 1 Dynamic parameters of midazolam after treated with BBR or ketoconazole in rats 
(x ± s, n = 8)
Compared with the negative control group, * p < 0.05, ** p < 0.01, *** p < 0.001










AUC(0−t) (μg/mL h) 1.25 ± 0.29 1.69 ± 0.31 2.03 ± 0.44*** 2.12 ± 0.66*** 2.47 ± 0.49***
AUMC(0−t) (μg/mL h) 1.24 ± 0.37 1.49 ± 0.29 1.98 ± 0.56** 2.08 ± 0.75** 2.57 ± 0.65***
CLz (L/h/kg) 14.89 ± 4.93 11.23 ± 1.8* 9.19 ± 2.31*** 9.33 ± 4.09** 7.17 ± 1.85***
Vz (L/kg) 20.51 ± 3.63 12.58 ± 3.05*** 12.12 ± 3.28*** 13.05 ± 3.74*** 10.85 ± 2.37***
t1/2 (min) 61 ± 18 47 ± 11 56 ± 14 61 ± 12 66 ± 23
tmax (min) 13 ± 5 12 ± 5 12 ± 6 11 ± 5 10 ± 3
Cmax (μg/mL) 1.13 ± 0.25 1.69 ± 0.23** 1.84 ± 0.29*** 2.12 ± 0.53** 2.21 ± 0.29***
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impact on half-life period (t1/2) and the time to reach peak concentration (tmax). AUC(0−t), 
AUMC(0−t) and Cmax of MDZ in the 200 mg/kg group increased by 69.6, 67.7 and 87.6 % 
respectively, while the clearance rate and apparent volume of distribution of MDZ 
reduced by 37.3 and 36.4 % respectively.
Meanwhile, BBR could decrease AUC(0−t) and AUMC(0−t) of 1′-OH-MDZ significantly 
(p < 0.05) in a dose-dependent way, and expedite the clearance rate of 1′-OH-MDZ while 
it gained apparent volume of distribution (p < 0.05), but had no significant impact on 
t1/2 and Tmax. AUC(0−t), AUMC(0−t) and Cmax of 1′-OH-MDZ in the 200  mg/kg group 
reduced by 45.5, 45.6 and 37.3 % respectively while the clearance rate and apparent vol-
ume of distribution of 1′-OH-MDZ increased by 70.4 and 71.4 % respectively.
Effect of berberine on the Rh123 pharmacokinetic experiments in rats
Pre-treated with different doses of BBR or verapamil raised the rat plasma concentra-
tion of Rh123 (Fig. 3). Pre-treated with BBR at 200 mg/kg or verapamil, the concentra-
tion was significantly higher than that in the negative group at the time point of 1 h and 
lasted to 48 h (p < 0.05). Furthermore, the increased concentration of Rh123 with high 
doses of BBR was similar to the increased concentration with positive drug verapamil at 
20 min after gavage treatment. In conclusion, BBR could increase the plasma concentra-
tion of Rh123.
Table 2 Dynamic parameters of 1’-hydroxymidazolam after treated with BBR or ketocona-
zole in rats (x ± s, n = 8)
Compared with the negative control group, * p < 0.05, ** p < 0.01, *** p < 0.001










AUC(0−t) (μg/mL h) 0.66 ± 0.28 0.46 ± 0.19* 0.42 ± 0.11** 0.36 ± 0.09*** 0.37 ± 0.10***
AUMC(0−t) (μg/mL h) 0.68 ± 0.34 0.47 ± 0.22* 0.41 ± 0.12** 0.37 ± 0.11** 0.37 ± 0.12**
CLz (L/h/kg) 29.93 ± 11.89 44.9 ± 20.95* 45.17 ± 10.85* 50.99 ± 11.90** 50.66 ± 12.94***
Vz (L/kg) 41.61 ± 12.07 67.57 ± 32.43* 63.75 ± 18.66* 71.33 ± 26.01* 75.57 ± 23.57**
t1/2 (min) 61 ± 17 62 ± 8 58 ± 11 57 ± 12 61 ± 7
tmax (min) 17 ± 5 11 ± 4 12 ± 6 12 ± 7 13 ± 7
Cmax (μg/mL) 0.51 ± 0.16 0.44 ± 0.13 0.40 ± 0.08* 0.32 ± 0.07*** 0.33 ± 0.09**
Fig. 3 The effect of multi‑dose of berberine or verapamil on the pharmacokinetics of rhodamine 123 in rats. 
Data present mean concentrations ± SD, n = 8
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Table 3 showed the altered pharmacokinetic parameters of Rh123 after giving diverse 
drugs. In contrast to the negative group, 100, 200  mg/kg BBR and the positive vera-
pamil group significantly increased the AUC(0−t) and AUC(0−∞) of Rh123 (p  <  0.001), 
but reduced its clearance rate and apparent volume of distribution (p < 0.01). In addi-
tion, pre-treated with BBR, except at dose of 50 mg/kg, or verapamil could increase Cmax 
of Rh123 (p < 0.05). Besides that, BBR had no significant influence with half-life period 
of Rh123, but the positive drug verapamil significantly prolonged the half-life period 
of Rh123 (p  <  0.01). AUC(0−t), AUC(0−∞) and Cmax of Rh123 in the 200  mg/kg group 
increased by 97.5, 101.7 and 268.5 % respectively, while the clearance rate and apparent 
volume of distribution of Rh123 reduced by 49.7 and 28.3 % respectively.
Cytochrome P450 3A (CYP3A) is the most abundant hepatic and intestinal phase I 
drug-metabolizing enzyme. It participates in the metabolism of approximately 50 % of 
drugs on the market and in the oxidation of endogenous and exogenous compounds. 
Many drugs are metabolized by CYP3A, an enzyme whose activity can affect many 
drugs’ effect and consequentially cause drug toxicity within patients. The enzyme’s activ-
ity can be induced or inhibited by many drugs, which would take part in a drug–drug 
interaction. P-gp is mainly distributed in the cell membrane and belongs to the ATP 
binding cassette (ABC) transporter superfamily member (Schwab et  al. 2003). P-gp is 
found in various tissues such as the liver, brain, kidney and small intestine (Matheny 
et al. 2012). P-gp can reduce drug absorption in the intestine and increase drug elimina-
tion by the liver cell membrane.
CyclosporineA (CsA) is one of the most widely used immunosuppressants in organ 
transplant recipients. In years of clinical practice, we have found that BBR can signifi-
cantly increase plasma concentration of CsA in transplant recipients. The combination 
of BBR and CsA can lower the necessary dosage of CsA to achieve a similar result. As 
a result, the combination can be an efficient means to economize the high cost of CsA 
(Wu et  al. 2005). CYP3A and P-gp regulated the absorption and metabolism of CsA, 
which is the substrate of CYP3A and P-gp. Studies have shown that as a result of trans-
plant recipients taking CsA, 56 % of the apparent oral clearance difference is induced by 
liver CYP3A4 enzyme activity and 17 % is induced by P-gp activity of the small intestine. 
Similarly, as a result of transplant recipients taking CsA, 32 % of the Cmax difference was 
induced by liver CYP3A4 enzyme activity and 17 % is induced by P-gp activity of the 
small intestine (Lown et al. 1997). Therefore, CYP3A and P-gp play an important role in 
Table 3 Pharmacodynamic parameters of Rh123 after treated with berberine or verapamil 
in rats (x ± s, n = 8)
Compared with the negative control group, * p < 0.05, ** p < 0.01, *** p < 0.001










AUC(0‑t) (μg/L h) 48.36 ± 6.4 59.58 ± 13.37 77.51 ± 6.84*** 95.49 ± 15.99*** 93.01 ± 13.07***
AUC(0−∞) (μg/L h) 50.97 ± 6.99 63.52 ± 14.52 84.42 ± 7.72*** 102.8 ± 18.25*** 105.8 ± 14.79***
CLz (L/h/kg) 99.64 ± 14.01 81.95 ± 17.98* 59.63 ± 5.46*** 50.11 ± 10.54*** 47.96 ± 6.41***
Vz (L/kg) 1687 ± 219 1446 ± 347 1208 ± 293** 1209 ± 124*** 1204 ± 205**
t1/2 (h) 11.78 ± 0.89 12.39 ± 2.9 13.97 ± 2.73 14.47 ± 1.88 17.41 ± 1.79**
tmax (h) 1.4 ± 0.96 0.4 ± 0.09 0.5 ± 0.29 0.27 ± 0.15 0.4 ± 0.09
Cmax (μg/L) 4.41 ± 0.45 10.18 ± 5.59 11.78 ± 3.19* 16. 25 ± 8.65*** 11.39 ± 2.76*
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the ADME of CsA. We studied the influence of BBR on pharmacokinetics of MDZ and 
Rh123, which acts as the probes of CYP3A and P-gp respectively. The study explains the 
influence of BBR on the drug metabolism of CYP3A and P-gp in rats directly.
MDZ, a sedative-hypnotic drug, was mainly used for induction of anesthesia and pre-
operative administration. More and more researchers had used MDZ as a probe to study 
the function of CYP3A (Lee et al. 2002). MDZ was entirely metabolized by CYP3A but 
not the substrate of P-gp (Zhang et al. 2007). MDZ would be an ideal probe of CYP3A 
in a vivo or vitro study. MDZ is metabolized by CYP3A4 in the human body and by 
CYP3A1/2 in rats and mice. 1′-OH-MDZ was the main metabolite of MDZ (Chovan 
et al. 2007). Analyzing the variation of MDZ and 1′-OH-MDZ can evaluate the influence 
of drugs on CYP3A indirectly.
As a traditional Chinese medicine, BBR was widely used to treat diarrhea in clinical prac-
tice. Studies had shown that BBR had others pharmacology functions, such as anti-heart 
failure, anti-inflammatory, anti-platelet aggregation, lowering cholesterol and improv-
ing insulin resistance in recent years. We found that BBR could significantly increase the 
plasma concentration of CsA in renal transplantation patients, and could greatly improve 
the bioavailability of CsA without increasing the liver toxicity of CsA (Wu et al. 2005). In 
renal transplant recipients and healthy subjects, the pharmacokinetic study of CsA had 
also verified that the synergistic effect of BBR on the CsA (Xin et al. 2006). Since CsA was 
transported and metabolized by CYP3A and P-gp after oral absorption, we used MDZ as 
a CYP3A probe and Rh123 as a P-gp probe to study the effect of BBR on MDZ and Rh123.
In each BBR group, MDZ and 1′-OH-MDZ plasma concentration curves were between 
the negative control group and the positive control group. The plasma concentration of 
MDZ increased with the increasing doses of BBR, and the corresponding plasma con-
centration of 1′-OH-MDZ decreased with the increasing doses of BBR. In the high dose 
group of BBR, AUC(0−t) and Cmax of MDZ were significantly higher than that of the nega-
tive control group (p < 0.01). The clearance rate and the apparent volume of distribution 
decreased with increasing doses of BBR (p < 0.05). It showed that BBR could inhibit the 
MDZ clearance speed but it did not increase the rate of accumulation in the body. How-
ever, there was no significant difference in the half-life (t1/2) of MZD and Tmax. Accord-
ingly, in each BBR group, the AUC(0−t) of 1′-OH-MDZ was significantly lower than the 
negative control group (p < 0.05), the Cmax in the high dose group was decreased, and 
the clearance rate and the apparent volume of distribution increased with the increasing 
doses of BBR (p < 0.05). BBR had no significant influence on t1/2 and tmax.
In the low dose BBR groups, the Rh123 plasma concentration curves almost coin-
cided with the negative control group. Low dosages of BBR had no significant increase of 
plasma concentration of Rh123. The Rh123 plasma concentration was increased gradu-
ally with increasing doses of BBR. 200 mg/kg BBR had almost equivalent effects with the 
positive control verapamil. This result showed that BBR dose-dependently inhibited the 
activity of P-gp. In the middle and high dose BBR groups, AUC(0−t) of Rh123 was sig-
nificantly higher than that in the negative control group (p < 0.01). Cmax increased with 
the increasing doses of BBR. In the middle and high dose BBR groups, the clearance rate 
of Rh123 and the apparent volume of distribution (except for the low dose BBR group) 
decreased with the increasing doses of BBR (p < 0.05). This result also showed that BBR 
could inhibit Rh123 but not increase the accumulation in the body.
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The above results showed that BBR inhibited the metabolism of MDZ and Rh123 in 
rats, and these effects were likely to be the inhibitory effect of BBR on CYP3A activity 
and P-gp. Our previous studies had shown that Schisandrin A was able to significantly 
inhibit MDZ metabolism in rats and that 8, 16, 32 mg/kg of Schisandrin A could make 
AUC(0−t) of MDZ increase by 64.12, 86.88 %, 105.30 % respectively (Li et al. 2012). In 
this experiment, low, middle and high doses of BBR increased AUC(0−t) of MDZ by 
35.2, 62.4, 69.6 % respectively, and reduced AUC(0−t) of 1′-OH-MDZ by 30.3, 36.4, and 
45.5 % respectively. Low, middle and high doses of BBR increased AUC(0−t) of Rh123 
by 23.2, 47.9, 97.5 % respectively, and Cmax was significantly increased. Thus, the inhi-
bition of BBR on P-gp in low dose group is not strong. It was obvious that the inhibi-
tory effect was dependent on the dosage of BBR. In addition, a study on the effect of 
BBR on P-gp in vivo had also reached the following results: using gavage with 100 mg/
kg BBR for 2 weeks, the AUC(0−t) of P-gp substrate digoxin increased by 69.18 % (Qiu 
et al. 2009), and this result was in strong agreement with our result of 100 mg/kg BBR 
10 days after intragastric administration. However, the above study showed that after 
a 2-week pretreatment with BBR, the pharmacokinetic parameters of i.g. adminis-
tered carbamazepine (CBZ, a substrate of CYP3A) and its metabolite carbamazepine 
10,11-epoxide (ECBZ) were not significantly altered (Qiu et al. 2009). The reason for 
no significant changes in CYP3A activity by berberine using CBZ as a probe needs to 
be study further.
Conclusions
Our data showed that the metabolism of MDZ (a probe of CYP3A) and Rh123 (a probe 
drug of P-gp) was controlled by BBR in rats. It could be due to the inhibition by BBR on 
CYP3A enzymes and P-gp transporter. Once further research confirms the inhibitory 
effect of BBR on P-gp or CYP3A4 in the human body, it would help to clarify the mecha-
nism of enhancement of BBR on CsA in renal transplantation patients and thereby pro-




Healthy male Sprague–Dawley rats, weighing 250–280 g and 2–3 months of age, were 
purchased from Laboratory Animal Research Center of Wuhan University (Wuhan, 
China). The rats were housed in an accredited Laboratory Animal Center under con-
trolled temperature (22 ±  2  °C) and a 12-h dark/light cycle. All animals were allowed 
to acclimate for a minimum of 3 days before the studies were initiated. The studies were 
designed in accordance with the protocols approved by the Wuhan General Hospital 
Institutional Review Board—Use and Care of Animal Committee and all experimental 
protocols involving animals were approved by the Ethics Committee of Wuhan General 
Hospital. The whole pharmacokinetic study was designed according to the Guidance for 
Industry Drug Interaction Studies from US FDA (2012) and the relevant guideline for 
pharmacokinetics and metabolic studies in human and animals from European Medi-
cines Agency and Chinese FDA.
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Effects of berberine on midazolam and its metabolite
The rats were randomly divided into five groups with eight rats in each group. The rats 
in the treated groups were gavaged once daily with BBR at 50, 100 or 200 mg/kg for 10 
consecutive days, and the rats were gavaged similarly with equal volumes of vehicle in 
the negative control group or ketoconazole (75 mg/kg) in the positive control group. On 
day 10, the rats were intraperitoneal injection with 2 % urethane dissolved. 30 min after 
the rats were treated with their respective drugs, midazolam was administered using sin-
gle-pass duodenum perfusion at 20 mg/kg. Blood samples of about 0.6 ml were drawn 
from the femoral artery at 0, 2, 5, 10, 20, 30, 60, 90, 120 and 180 min after administration 
of midazolam. The rats were administrated with 3  ml of glucose saline (10  % glucose 
solution:physiological saline  =  3:7) at 30  min. Blood samples were immediately hep-
arinized and centrifuged at 3000 rpm/min for 10 min at 4 °C to obtain plasma samples, 
which were frozen at −40 °C until HPLC analysis.
Effects of berberine on rhodamine 123
The rats were randomly divided into five groups with eight rats in each group. The rats in 
the treated groups were administrated in the same way for 10 consecutive days, and rats 
were gavaged similarly with equal volume of verapamil (4 mg/kg) in the positive control 
group. 30 min after the rats were treated with their respective drugs, Rh123 (5 mg/kg) 
was orally administrated. Blood samples were drawn from the caudal vein at 0, 5, 10, 20, 
30, 60, 90 min and 3, 6, 9, 12, 18, 24, 36, 48 h after administration of Rho123, then the 
samples were immediately heparinized and plasma samples were obtained, which were 
frozen at −40 °C until HPLC analysis.
Sample processing and HPLC analysis
The plasma sample (250 μl) from 1.3.1 was mixed with 20 μl of internal standard solu-
tion (diazepam) before the addition of 200 μl of buffer bicarbonate (pH 10) to alkalify 
the plasma drug and then 5 ml mixture (dichloromethane:hexane = 7:3, v/v) was mixed 
and shaken for 5 min. After vortex-mixing, the mixture was centrifuged at 3000×g for 
10 min. After the upper aqueous phase had been removed, 4.5 ml of the organic phase 
was transferred to another tube and completely evaporated under nitrogen gas. The resi-
due was dissolved in 250 μl of the mobile phase and 50 μl was injected into the HPLC 
system.
The HPLC analytical method for plasma 1′-hydroxymidazolam and MDZ was 
improved from an earlier report (Juřica et al. 2007), and it was described in our previous 
report (Li et al. 2012). A Hypersil BDS C18 column 4.6 mm × 250 mm equipped with a 
guard column, C18 BDS guard column 4.6 mm × 10 mm was kept at 40 °C. The mobile 
phase consisted of acetonitrile, methanol and 20  mM phosphate buffer (pH  =  3.9) 
(20:42:38, v/v) and was pumped at a constant rate of 1.0 ml/min. The detection wave-
length was set at 230 nm.
The HPLC analytical method for plasma Rh123 was described in our previous report 
(Xin et al. 2014). 150 μl of samples from 1.3.2 were mixed with 150 μl acetonitrile for 
5  min to precipitate protein. After forming flocculent precipitate, 20  μl of superna-
tant was injected into the chromatographic column, a Hypersil BDS C18 column 
4.6 ×  150  mm, kept at 25  °C. The mobile phase consisted of acetonitrile and 20  mM 
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phosphate buffer (pH = 4.0) (60:40, v/v) and was pumped at a constant rate of 1.0 ml/
min. The fluorescence detection wavelength was set at 485 nm for excitation and 546 nm 
for emission.
Statistical analysis
The estimation of pharmacokinetic parameters was conducted using DAS (Drug and 
Statistics) 2.0 analysis soft (Shanghai, China). One-way ANOVA followed by post hoc 
least significant difference (LSD) tests was used to determine group differences based on 
the assumption of equal variances for the pharmacokinetic parameters, and Tamhane’s 
T2 test was used in the case of unequal variances (SPSS 13.0). A p < 0.05 was considered 
statistically significant.
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